News | August 13, 2025
Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Commenced operations in flood-affected Himachal Pradesh
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Subscribe To Our Newsletter & Stay Updated
